… ProQR Announces Results for the Fourth Quarter and Full Year … LEIDEN, the Netherlands, Feb. 28, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced results … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-110, our second development program targeting …
… ProQR Announces Results for the Fourth Quarter and Full Year … Partnership with Foundation Fighting Blindness (FFB) where ProQR will receive up to $7.5 million in funding for the … of 2017 and Business Update QR-110 for LCA 10 In April, ProQR’s QR-110 for Leber’s congenital amaurosis 10 (LCA 10) …
… ProQR Strengthens Leadership with Appointments of CFO and CMO … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “Dennis brings deep expertise in corporate finance and …
… ProQR Highlights New Platform Data from Presentation on … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR. “To date, we have generated robust in vitro and in …
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen … & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … of sepofarsen. This marks an important milestone for ProQR, as well as for the LCA10 and broader inherited retinal …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR presents in vivo data in a relevant disease model, … The Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that a …
… ProQR Announces Results for the Third Quarter of 2015 and … LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … studies," said Daniel de Boer, Chief Executive Officer of ProQR. “Our teams have taken a number of steps to accelerate …
… ProQR Provides Enrollment Update on QR-110 Clinical Trial and … and retinal structure in the second half of the year. ProQR to present two abstracts on programs for Fuchs … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We look forward to the clinical data for the QR-110 …
… ProQR to Present Findings from Phase 1/2 Interim Analysis of … & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … page on the Investors section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Receives Orphan Drug Designation from FDA for QR-1123 … Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or adRP,” said Daniel de Boer, Chief Executive Officer of ProQR. “It highlights the unmet need for patients with this …